eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
4/2024
vol. 75
 
Share:
Send email
Share:
Original paper

Predicting TNFRSF4 expression and prognosis in head and neck squamous cell carcinoma tissue: a pathological image analysis approach

Weiming Chu
1
,
Chen Chu
1
,
Zongmei Ding
2
,
Wei Guan
1
,
Shiyuan Li
1
,
Jixin Jiang
2
,
Yu Xue
1
,
Jianping Qiu
1
,
Aijun Guo
1

  1. Department of Stomatology, Northern Jiangsu People's Hospital, China, P.R. China
  2. Department of Pathology, Northern Jiangsu People's Hospital, P.R. China
Pol J Pathol 2024; 75 (4): 287-304
DOI: https://doi.org/10.5114/pjp.2024.146147
Online publish date: 2024/12/30
Article file
- Predicting TNFRSF4.pdf  [0.43 MB]
Get citation
 
PlumX metrics:
 
1. Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 2020; 6: 92.
2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
3. Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
4. Qi Z, Liu Y, Mints M, et al. Single-cell deconvolution of head and neck squamous cell carcinoma. Cancers (Basel) 2021; 13.
5. Puntigam LK, Jeske SS, Gotz M, et al. Immune checkpoint expression on immune cells of HNSCC patients and modulation by chemo- and immunotherapy. Int J Mol Sci 2020; 21.
6. Bell RB, Leidner RS, Crittenden MR, et al. OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment. Oral Oncol 2016; 52: 1-10.
7. Petty JK, He K, Corless CL, et al. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg 2002; 183: 512-518.
8. Weinberg AD, Rivera MM, Prell R, et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 2000; 164: 2160-2169.
9. Li H, Chen L, Zeng H, et al. Integrative analysis of histopathological images and genomic data in colon adenocarcinoma. Front Oncol 2021; 11: 636451.
10. Zeng H, Chen L, Huang Y, et al. Integrative models of histopathological image features and omics data predict survival in head and neck squamous cell carcinoma. Front Cell Dev Biol 2020; 8: 553099.
11. Li Y, Du P, Zeng H, et al. Integrative models of histopatholo­gical images and multi-omics data predict prognosis in endometrial carcinoma. PeerJ 2023; 11: e15674.
12. Kuss I, Hathaway B, Ferris RL, et al. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004; 10: 3755-3762.
13. Bauernhofer T, Kuss I, Henderson B, et al. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol 2003; 33: 119-124.
14. Schaefer C, Kim GG, Albers A, et al. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005; 92: 913-920.
15. Jie HB, Gildener-Leapman N, Li J, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 2013; 109: 2629-2635.
16. Bansal-Pakala P, Halteman BS, Cheng MH, et al. Costimulation of CD8 T cell responses by OX40. J Immunol 2004; 172: 4821-4825.
17. Polesso F, Sarker M, Weinberg AD, et al. OX40 agonist tumor immunotherapy does not impact regulatory T cell suppressive function. J Immunol 2019; 203: 2011-2019.
18. Nuebling T, Schumacher CE, Hofmann M, et al. The immune checkpoint modulator OX40 and its ligand OX40L in NK-cell immunosurveillance and acute myeloid leukemia. Cancer Immunol Res 2018; 6: 209-221.
19. Aspeslagh S, Postel-Vinay S, Rusakiewicz S, et al. Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer 2016; 52: 50-66.
20. Bansal-Pakala P, Jember AG, Croft M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat Med 2001; 7: 907-912.
21. Lai C, August S, Albibas A, et al. OX40+ regulatory T cells in cutaneous squamous cell carcinoma suppress effector T-cell responses and associate with metastatic potential. Clin Cancer Res 2016; 22: 4236-4248.
22. Marabelle A, Kohrt H, Sagiv-Barfi I, et al. Depleting tumor- specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013; 123: 2447-2463.
23. Xie F, Wang Q, Chen Y, et al. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract 2010; 206: 735-739.
24. Bulliard Y, Jolicoeur R, Zhang J, et al. OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol 2014; 92: 475-480.
25. Coudray N, Ocampo PS, Sakellaropoulos T, et al. Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat Med 2018; 24: 1559-1567.
26. Kim RH, Nomikou S, Coudray N, et al. Deep learning and pathomics analyses reveal cell nuclei as important features for mutation prediction of BRAF-mutated melanomas. J Invest Dermatol 2022; 142: 1650-1658.e6.
27. Schaumberg AJ, Sirintrapun SJ, Al-Ahmadie HA, et al. DeepScope: nonintrusive whole slide saliency annotation and prediction from pathologists at the microscope. Comput Intell Methods Bioinform Biostat (2016) 2017; 10477: 42-58.
28. Dolezal JM, Trzcinska A, Liao CY, et al. Deep learning prediction of BRAF-RAS gene expression signature identifies noninvasive follicular thyroid neoplasms with papillary-like nuclear features. Mod Pathol 2021; 34: 862-874.
29. Kather JN, Pearson AT, Halama N, et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med 2019; 25: 1054-1056.
30. Cao R, Yang F, Ma SC, et al. Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer. Theranostics 2020; 10: 11080-11091.
31. Inamura K, Fujiwara T, Hoshida Y, et al. Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non- negative matrix factorization. Oncogene 2005; 24: 7105-7113.
32. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8: 816-824.
33. Chen S, Jiang L, Zheng X, et al. Clinical use of machine learning-based pathomics signature for diagnosis and survival prediction of bladder cancer. Cancer Sci 2021; 112: 2905-2914.
34. Wu Y, Li Y, Xiong X, et al. Recent advances of pathomics in colorectal cancer diagnosis and prognosis. Front Oncol 2023; 13: 1094869.
35. Echle A, Grabsch HI, Quirke P, et al. Clinical-grade detection of microsatellite instability in colorectal tumors by deep learning. Gastroenterology 2020; 159: 1406-1416.e11.
36. Jiang W, Mei WJ, Xu SY, et al. Clinical actionability of triag­ing DNA mismatch repair deficient colorectal cancer from biopsy samples using deep learning. EBioMedicine 2022; 81: 104120.
37. Yamashita R, Long J, Longacre T, et al. Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study. Lancet Oncol 2021; 22: 132-141.
38. Bilal M, Raza SEA, Azam A, et al. Development and validation of a weakly supervised deep learning framework to predict the status of molecular pathways and key mutations in colorectal cancer from routine histology images: a retrospective study. Lancet Digit Health 2021; 3: e763-e772.
39. Huang X, Chen Z, Xiang X, et al. Comprehensive multi-omics analysis of the m7G in pan-cancer from the perspective of predictive, preventive, and personalized medicine. EPMA J 2022; 13: 671-697.
40. Poropatich K, Dominguez D, Chan WC, et al. OX40+ plasmacytoid dendritic cells in the tumor microenvironment promote antitumor immunity. J Clin Invest 2020; 130: 3528-3542.
41. Theate I, van Baren N, Pilotte L, et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res 2015; 3: 161-172.
42. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008; 27: 3889-3900.
43. Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tole­rance and counter-regulation. Curr Opin Immunol 2006; 18: 220-225.
44. Spranger S, Koblish HK, Horton B, et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014; 2: 3.
45. Chu W, Song X, Yang X, et al. Neuropilin-1 promotes epithelial-to-mesenchymal transition by stimulating nuclear factor- kappa B and is associated with poor prognosis in human oral squamous cell carcinoma. PLoS One 2014; 9: e101931.
46. Mandal R, Senbabaoglu Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016; 1: e89829.
47. Peri S, Izumchenko E, Schubert AD, et al. NSD1- and NSD2- damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nat Commun 2017; 8: 1772.
48. Vossen DM, Verhagen CVM, Verheij M, et al. Comparative genomic analysis of oral versus laryngeal and pharyngeal cancer. Oral Oncol 2018; 81: 35-44.
49. Kim HAJ, Zeng PYF, Shaikh MH, et al. All HPV-negative head and neck cancers are not the same: analysis of the TCGA dataset reveals that anatomical sites have distinct mutation, transcriptome, hypoxia, and tumor microenvironment profiles. Oral Oncol 2021; 116: 105260.
50. Sorgini A, Kim HAJ, Zeng PYF, et al. Analysis of the TCGA dataset reveals that subsites of laryngeal squamous cell carcinoma are molecularly distinct. Cancers (Basel) 2020; 13.
51. Deneka AY, Baca Y, Serebriiskii IG, et al. Association of TP53 and CDKN2A mutation profile with tumor mutation burden in head and neck cancer. Clin Cancer Res 2022; 28: 1925-1937.
Copyright: © 2024 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.